Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 120 results for multiple sclerosis

  1. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...

  2. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...

  3. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...

  4. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...

  5. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Register an interest in this interventional procedure NICE has been notified about the above procedure and considered it part of the In...

  6. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

      Status ...

  7. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....

  8. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  9. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  10. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

  11. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

  12. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

      Status ...

  13. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  14. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...